Mr. Paul Reichert, MS

Associated Principal Scientist
Merck Research Laboratories
Kenilworth New Jersey UNITED STATES
Message Notes
Paul Reichert is an Associate Principal Scientist in the Biochemical Engineering and Structure Department at Merck Research Laboratories (MRL). He has been conducting pharmaceutical research for 35 years working at MRL on the discovery and development of small molecule and macromolecular therapeutics. His expertise is primarily in the area of crystallization of proteins and biologics to better patient treatment options for efficacy, safety, adherence and compliance. Paul has over 25 pharmaceutical application patents of crystalline proteins and is also the author of over 31 papers on the development of biologic therapeutics. He established a high throughput (HT) crystallization lab to research and develops HT macromolecular crystallization strategies and screening methodologies. As an integral member of a multidisciplinary team, he developed novel, controlled release biological health care technologies and brought them to market. Most noteworthy, he was a member of a team which developed the manufacturing process for alpha interferon product; Intron A™ and PEG Intron A™. The alpha-2 interferon products, for example, fulfilled an unmet medical need for hepatitis C and melanoma patients. For 15 years, in collaboration with NASA and the University of Alabama at Birmingham, he has had both advisory and scientific roles. He was a member of the Science Advisory Group for NASA's Iterative Biological Crystallization Group at Marshall Space Flight Center. He has been a principal investigator for eleven microgravity experiments on Space Shuttle flights as secondary payloads. These experiments were designed to explore microgravity effects on multiple pharmaceutical applications primarily using alpha interferon (Intron A™). These patient-centric applications included structure determination, drug delivery and the purification of protein therapeutics with implications for health economics and outcomes. Currently, besides his work at MRL, Paul is a principal investigator in collaboration with CASIS and has performed experiments for crystallization of therapeutic monoclonal antibodies on Space X-CRS-3and 6 and 10 mission to the International Space Station (ISS).
Add to myBIO Planner Notes
None yet.